CUSIP: 05337G107
Q3 2014 13F Holders as of 30 Sep 2014
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
12,525,268
-
Share change
-
+12,525,268
-
Total reported value
-
$420,320,000
-
Price per share
-
$34.19
-
Number of holders
-
58
-
Value change
-
+$420,320,000
-
Number of buys
-
58
Quarterly Holders Quick Answers
What is CUSIP 05337G107?
CUSIP 05337G107 identifies AAVL - AVALANCHE BIOTECHNOLOGIES IN - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 05337G107:
Institutional Holders of AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) as of Q3 2014
As of 30 Sep 2014,
AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) was held by
58 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,525,268 shares.
The largest 10 holders included
FMR LLC, DEERFIELD MANAGEMENT CO, VHCP Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, ADAGE CAPITAL PARTNERS GP LLC, Redmile Group, LLC, JPMORGAN CHASE & CO, FRONTIER CAPITAL MANAGEMENT CO LLC, Tourbillon Capital Partners LP, and COWEN GROUP, INC..
This page lists
58
institutional shareholders reporting positions in this security
for the Q3 2014 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.